Should nivolumab be discontinued in a patient who develops bullous pemphigoid but is otherwise responding well to therapy, if BP is being managed with dupilumab?

Nivolumab should be discontinued in a patient with grade 3-4 bullous pemphigoid, but may be held rather than permanently discontinued for grade 2 disease, even when the bullous pemphigoid is being managed with dupilumab.

The National Comprehensive Cancer Network guidelines specify that discontinuati...